391 related articles for article (PubMed ID: 9643376)
1. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
Van Rompay KK; Marthas ML; Lifson JD; Berardi CJ; Vasquez GM; Agatep E; Dehqanzada ZA; Cundy KC; Bischofberger N; Pedersen NC
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):761-73. PubMed ID: 9643376
[TBL] [Abstract][Full Text] [Related]
2. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.
Van Rompay KK; Berardi CJ; Aguirre NL; Bischofberger N; Lietman PS; Pedersen NC; Marthas ML
AIDS; 1998 Jun; 12(9):F79-83. PubMed ID: 9662190
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Van Rompay KK; Miller MD; Marthas ML; Margot NA; Dailey PJ; Canfield DR; Tarara RP; Cherrington JM; Aguirre NL; Bischofberger N; Pedersen NC
J Virol; 2000 Feb; 74(4):1767-74. PubMed ID: 10644348
[TBL] [Abstract][Full Text] [Related]
4. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.
Van Rompay KK; McChesney MB; Aguirre NL; Schmidt KA; Bischofberger N; Marthas ML
J Infect Dis; 2001 Aug; 184(4):429-38. PubMed ID: 11471100
[TBL] [Abstract][Full Text] [Related]
5. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.
Van Rompay KK; Cherrington JM; Marthas ML; Lamy PD; Dailey PJ; Canfield DR; Tarara RP; Bischofberger N; Pedersen NC
Antimicrob Agents Chemother; 1999 Apr; 43(4):802-12. PubMed ID: 10103184
[TBL] [Abstract][Full Text] [Related]
6. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.
Van Rompay KK; Cherrington JM; Marthas ML; Berardi CJ; Mulato AS; Spinner A; Tarara RP; Canfield DR; Telm S; Bischofberger N; Pedersen NC
Antimicrob Agents Chemother; 1996 Nov; 40(11):2586-91. PubMed ID: 8913470
[TBL] [Abstract][Full Text] [Related]
7. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.
van Rompay KK; Dailey PJ; Tarara RP; Canfield DR; Aguirre NL; Cherrington JM; Lamy PD; Bischofberger N; Pedersen NC; Marthas ML
J Virol; 1999 Apr; 73(4):2947-55. PubMed ID: 10074144
[TBL] [Abstract][Full Text] [Related]
8. Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.
Lifson JD; Piatak M; Cline AN; Rossio JL; Purcell J; Pandrea I; Bischofberger N; Blanchard J; Veazey RS
J Med Primatol; 2003 Aug; 32(4-5):201-10. PubMed ID: 14498980
[TBL] [Abstract][Full Text] [Related]
9. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Tsai CC; Follis KE; Sabo A; Beck TW; Grant RF; Bischofberger N; Benveniste RE; Black R
Science; 1995 Nov; 270(5239):1197-9. PubMed ID: 7502044
[TBL] [Abstract][Full Text] [Related]
10. Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques.
Silvera P; Racz P; Racz K; Bischofberger N; Crabbs C; Yalley-Ogunro J; Greenhouse J; Jiang JB; Lewis MG
AIDS Res Hum Retroviruses; 2000 May; 16(8):791-800. PubMed ID: 10826485
[TBL] [Abstract][Full Text] [Related]
11. Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques.
Smith MS; Foresman L; Lopez GJ; Tsay J; Wodarz D; Lifson JD; Page A; Wang C; Li Z; Adany I; Buch S; Bischofberger N; Narayan O
Virology; 2000 Nov; 277(2):306-15. PubMed ID: 11080478
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.
Rosenwirth B; ten Haaft P; Bogers WM; Nieuwenhuis IG; Niphuis H; Kuhn EM; Bischofberger N; Heeney JL; Uberla K
J Virol; 2000 Feb; 74(4):1704-11. PubMed ID: 10644340
[TBL] [Abstract][Full Text] [Related]
13. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.
Tarantal AF; Marthas ML; Shaw JP; Cundy K; Bischofberger N
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):323-33. PubMed ID: 10096575
[TBL] [Abstract][Full Text] [Related]
14. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
[TBL] [Abstract][Full Text] [Related]
15. Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
Kumar A; Buch S; Foresman L; Bischofberger N; Lifson JD; Narayan O
Virology; 2001 Jan; 279(1):97-108. PubMed ID: 11145893
[TBL] [Abstract][Full Text] [Related]
16. Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.
Van Rompay KK; Schmidt KA; Lawson JR; Singh R; Bischofberger N; Marthas ML
J Infect Dis; 2002 Nov; 186(10):1508-13. PubMed ID: 12404171
[TBL] [Abstract][Full Text] [Related]
17. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.
Van Rompay KK; Singh RP; Brignolo LL; Lawson JR; Schmidt KA; Pahar B; Canfield DR; Tarara RP; Sodora DL; Bischofberger N; Marthas ML
J Acquir Immune Defic Syndr; 2004 Aug; 36(4):900-14. PubMed ID: 15220696
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
Metzner KJ; Binley JM; Gettie A; Marx P; Nixon DF; Connor RI
Retrovirology; 2006 Dec; 3():97. PubMed ID: 17184540
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment.
Tsai CC; Emau P; Follis KE; Beck TW; Benveniste RE; Bischofberger N; Lifson JD; Morton WR
J Virol; 1998 May; 72(5):4265-73. PubMed ID: 9557716
[TBL] [Abstract][Full Text] [Related]
20. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
Subbarao S; Otten RA; Ramos A; Kim C; Jackson E; Monsour M; Adams DR; Bashirian S; Johnson J; Soriano V; Rendon A; Hudgens MG; Butera S; Janssen R; Paxton L; Greenberg AE; Folks TM
J Infect Dis; 2006 Oct; 194(7):904-11. PubMed ID: 16960777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
